trader_ron
2 months ago
$EBYH - Strainsforpains is a medical marijuana recommendation engine that guides patients to the appropriate cannabinoid levels, medical cannabis strains, and consumption methods for their specific ailment. Accessible via dedicated mobile APP, and desktop app, Strainsforpains utilizes a robust database of strains, cannabinoids, and medicinal applications aggregated through semantic web technology and validated by medical devices in research centers around the world.
https://www.strainsforpains.com/
Bansky
3 months ago
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.otcmarkets.com/otcapi/company/dns/news/document/73922/content
NEW YORK, April 15, 2024 (E-Buy Homes, Inc. DBA/Strainsforpains, Inc.) (OTC Markets: EBYH)
Strainsforpains, Inc. is pleased to announce that it has released its annual report, showing
increased sales of 1000% from $7400 in 2022 to $84,000 in 2023. The company has announced that its
first quarter 2024 has seen a $130,000 order for its CBD products as well.
Mr. Shainberg, Strainsforpains president stated that βWe anticipate 2024 to be a milestone year for
us, not just with major increases in revenues, but also joint ventures in developments of new
products, licensing agreements, upgrade to our pain management app utilizing the latest in
artificial intelligence, and the finalization of our seven acre Pennsylvania facility renovations
for manufacturing and distribution of CBD productsβ.
The company is working with scientists and doctors well known in their fields, in areas of water
solubility of CBD, as well as new anti-inflammatory additives to our CBD products. We have entered
into a licensing deal with GenBio, primarily a US-based biotech research Company, and its mission
is to develop the next generation of anti-inflammatory drugs.
Strainsforpains is also progressing towards its change of symbol on the OTC Markets, with its
upcoming audited financials within 2024.
mick
4 months ago
EBYH SECURITY DETAILS Share Structure
Market Cap Market Cap 1,937,753
03/21/2024
Authorized Shares 550,000,000
03/21/2024
Outstanding Shares 12,918,356
03/21/2024
Restricted 11,611,359
03/21/2024
Unrestricted 1,306,997
03/21/2024
Held at DTC 1,304,844
03/21/2024
Float1,306,997
06/26/2023
Par Value
0.001
BlazingStocks
6 months ago
Really like the $EBYH Share Structure!
Outstanding Shares 12,918,356 01/14/2024
Restricted 11,611,359 01/14/2024
Unrestricted 1,306,997 01/14/2024
Held at DTC 1,304,844 01/14/2024
https://www.otcmarkets.com/stock/EBYH/security
Bansky
6 months ago
Strainsforpains, Inc. Announces Corporate Update (NY, NY)-(January 11, 2024)(Strainsforpains, Inc.)(OTC Markets : EBYH).
Strainsforpains, Inc. is pleased to announce it has closed out 2023 with its largest orders to date, valued at $65,000, from various CBD and health markets, including Forces of Nature, Portokali, and other prominent establishments in New York City. This significant achievement marks a major milestone for our company and underscores the increasing demand for Strainsforpainsβ high-quality products. With this significant order, Strainsforpains will deliver its full spectrum products, renowned for their exceptional quality and effectiveness. The company continues its collaboration with Popped, a NYC company, to jointly develop products and services with anticipated sales of six hundred thousand dollars by the end of 2024. Mr. Shainberg, president of Strainsforpains, expressed his satisfaction, stating βWe are thrilled to conclude 2023 with our most substantial orders to date and anticipate an outstanding 2024, as we introduce our signature brand and product line to the marketβ. This order consists of a cream- based product, designed for pain relief related to muscle pain and bone ailments. It positions Strainsforpains to make a significant impact in the CBD industry and establish itself as a leader in effective pain relief solutions. The projected market demand for Strainsforpainsβ signature brand and product line is highly promising. With a commitment to meeting the growing demand for its signature brand and product line, Strainsforpains has ambitious plans for 2024. Our other CBD product line will feature watersoluble liposomal technology, an innovative nanoliposmal encapsulation that has been scientifically proven to increase the absorption of CBD by 80%. This cutting-edge technology distinguishes our products in the market, offering superior benefits to our clients. By diversifying its product offerings, the company aims to cater to a broader range of customer needs and solidify its position in the industry. The data technology division, which collaborates with hospitals and physicians, is also expected to experience a substantial increase in sales in 2024. Our app is currently being upgraded to position itself as a leading educational tool for pain management operations at hospitals and with doctors specializing in pain relief. The company collaborates with NYU, Teva Pharmaceuticals, and other major US and international organizations to share data. Poised for swift growth and success, Strainsforpains is embarking on its journey to offer a compelling range of products and services. The company acknowledges the powerful synergy between telehealth platforms and high-quality pain relief products, laying the foundation for a promising venture ahead. To meet the expected demand in 2024, Strainsforpains plans to increase production capacity. The ongoing rehabilitation of its 6-acre facility in Pennsylvania will enable potential use for manufacturing and distribution in the event of a significant increase in demand. This strategic move aims to scale up operations without compromising product quality. Strainsforpains has conducted extensive market research and analysis to support our optimistic projections for 2024. The CBD and THC market is constantly growing, with consumers increasingly seeking high-quality and unique products. Our commitment to innovation, superior quality, and customer satisfaction positions us well to capitalize on this market trend and drive substantial growth in the coming year. In summary, Strainsforpains, Inc. is delighted to announce the successful culmination of its largest orders to date, secured from establishments based in New York City. This accomplishment stands as a testament to the trust and confidence that our customers place in our products. Leveraging our full spectrum offerings, our cutting-edge water-soluble liposomal technology, and our data technology, we are strategically positioned to play a pivotal role in the dynamic CBD industry, poised for substantial growth in the upcoming year. Overview of Strainsforpains, Inc.: Please visit our website at http://www.strainsforpains.com/. Strainsforpains, Inc. is an innovative healthcare data technology Company located in New York, N.Y. The Company's objectives are to provide doctors, nurses, dispensaries, and patients access to an APP that will allow for an advanced determination of comparison of strains or brands of cannabis combinations with major illnesses, in a user-friendly manner. The company owns a 6.5acre facility in Pennsylvania that will be used for CBD product production. Mr. Shainberg is a member of the prestigious International Cannabinoid Research Society, https://icrs.co/ About International Cannabinoid Research Society. The organization is dedicated to scientific research of cannabinoids. It has 1300 research scientists among its members. https://icrs.co/ https://www.icrs2023.org/